XTL Biopharmaceuticals Ltd. (XTLB) Ownership
XTLB ownership summary
as of October 18, 2026- Institutions
- 0.3% of shares outstanding
- Insiders
- 21.44% of shares outstanding
- Shares outstanding
- 2.5M
- Float
- 1.7M shares available to trade
- Short interest
- 0.33% 6,050 shares short
- Days to cover
- 1.13 short interest down 15.6% vs prior month
- Institutions 0.27%
- Insiders 21.44%
- Other investors 78.29%
XTLB top institutional holders
9 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Rhumbline Advisers | 0.25% | 6,228 | $12,207 | +241 (+4.0%) | June 30, 2026 |
| 2 | GAMMA Investing LLC | 0.05% | 1,213 | $2,377 | −2,175 (−64.2%) | June 30, 2026 |
| 3 | UBS Group AG | 0.01% | 125 | $245 | +125 (0.0%) | June 30, 2026 |
| 4 | Morgan Stanley - Brokerage Accounts | 0.00% | — | — | −10 (−100.0%) | June 30, 2026 |
| 5 | Noked Israel Ltd | 0.00% | — | — | −49,722 (−100.0%) | June 30, 2026 |
| 6 | Tower Research Capital LLC | 0.00% | — | — | −244 (−100.0%) | June 30, 2026 |
| 7 | XTX Topco Ltd | 0.00% | — | — | −10,238 (−100.0%) | March 31, 2026 |
| 8 | SmartHarvest Portfolios, LLC | 0.00% | — | — | −13,351 (−100.0%) | June 30, 2026 |
| 9 | Citadel Advisors Llc | 0.00% | — | — | −75,866 (−100.0%) | March 31, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 9, 2 holders added 366 shares and 7 cut 152K.
XTLB top mutual fund and ETF holders
1 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Fidelity Nasdaq Composite Index | 0.06% | 1,439 | $2,820 | — | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
XTLB shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns XTLB
Institutional investors own 0.3% of XTL Biopharmaceuticals's shares and insiders 21.44%. The largest holder is Rhumbline Advisers with 0.25% of the shares (6,228), as of June 30, 2026. Among the top 9 institutions, 2 added shares and 7 reduced their stake in the latest filings. Short interest is 0.33% of the float, or 1.13 days of average trading volume. The share count rose 570,613.8% since 2014.
Related: XTLB key metrics. See the XTLB stock overview for the latest quote and news.
XTLB ownership FAQ
Who owns the most XTL Biopharmaceuticals stock?
The largest shareholders of XTL Biopharmaceuticals are Rhumbline Advisers (0.25%), GAMMA Investing LLC (0.05%), UBS Group AG (0.01%), Morgan Stanley - Brokerage Accounts (0.00%), Noked Israel Ltd (0.00%).
What percentage of XTL Biopharmaceuticals is owned by institutions?
Institutions hold 0.3% of XTL Biopharmaceuticals's shares outstanding; insiders hold 21.44%.
Which funds own XTL Biopharmaceuticals?
The largest fund holders of XTL Biopharmaceuticals are Fidelity Nasdaq Composite Index (0.06%).
What is XTL Biopharmaceuticals's short interest?
6,050 shares of XTL Biopharmaceuticals were sold short, 0.33% of the float; at the average daily volume it would take 1.13 days to cover.
How many shares of XTL Biopharmaceuticals are outstanding?
XTL Biopharmaceuticals has 2.5M shares outstanding, of which 1.7M are in the public float.